ASX Equity Snapshot
CUV Weekly Equity Report
Clinuvel Pharmaceuticals Limited
What the company does
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment …
What the weekly tape is saying
CUV closed the latest completed week at 8.96 AUD. The 4-week return is -5.4% and the 12-week return is -7.1%. Trend Signal is inactive, Market Dynamics is -0.40. Setup signature: Risk-first tape with a 26/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 10.61 AUD
- Vs Trend Line
- -15.5%
- Fair Value
- 13.25 AUD
- Vs Fair Value
- -32.4%
- 52W High
- 13.93 AUD
- 52W Low
- 8.35 AUD
- Drawdown
- -35.7%
- Range Position
- 10.9%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 22
- 52W Active Breadth
- 42.3%
- Sector Scope
- AU Healthcare
- Sector Rank
- 79 of 146
- Sector Percentile
- 46.2%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
AU Healthcare
- Tracked Peers
- 100
- 4W Rank
- 51 of 100
- Avg 1W
- -1.4%
- Avg 4W
- -3.6%
- Trend Breadth
- 15.0%
- Positive MD
- 39.0%
AU Biotechnology
- Tracked Peers
- 47
- 4W Rank
- 21 of 47
- Avg 1W
- -0.1%
- Avg 4W
- -5.8%
- Trend Breadth
- 10.6%
- Positive RS
- 21.3%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- -0.40
- 4W MD Change
- 59.1%
- Relative Strength
- -18.36
- 4W RS Change
- -41.9%
- Expectation
- Undecided
- Probability
- 49.03%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 453.0K
- 13W Average
- 422.2K
- 52W Average
- 539.6K
- Vs 13W
- 1.1x
- Vs 52W
- 0.8x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 3.1%
- 52W Volatility
- 5.6%
- Upside Weeks
- 26
- Downside Weeks
- 24
- Downside Breadth
- 46.2%
- Avg Gain / Loss
- 4.1% / -4.4%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- ASX
- Country
- AU
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- AUD
- Market Cap
- 460.4M
Opportunity signals
- No strong opportunity cluster is confirmed yet; monitor trend and Market Dynamics.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Market Dynamics is negative, which weakens the current setup.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 8.96 AUD | -1.9% | 10.61 AUD | 13.25 AUD | -0.40 | -18.36 | 453.0K | Off |
| 5 Jun 2026 | 9.13 AUD | 0.0% | 10.68 AUD | 13.31 AUD | -0.55 | -15.25 | 379.7K | Off |
| 29 May 2026 | 9.13 AUD | 0.3% | 10.73 AUD | 13.37 AUD | -0.71 | -16.47 | 344.9K | Off |
| 22 May 2026 | 9.10 AUD | -3.9% | 10.81 AUD | 13.42 AUD | -0.86 | -16.32 | 407.2K | Off |
| 15 May 2026 | 9.47 AUD | 0.0% | 10.89 AUD | 13.48 AUD | -0.97 | -12.94 | 291.8K | Off |
| 8 May 2026 | 9.47 AUD | 3.3% | 10.96 AUD | 13.54 AUD | -1.12 | -14.31 | 372.9K | Off |
| 1 May 2026 | 9.17 AUD | 1.4% | 11.06 AUD | 13.60 AUD | -1.26 | -17.24 | 346.8K | Off |
| 24 Apr 2026 | 9.04 AUD | -1.2% | 11.18 AUD | 13.67 AUD | -1.21 | -19.37 | 728.4K | Off |
| 17 Apr 2026 | 9.15 AUD | 0.7% | 11.25 AUD | 13.74 AUD | -1.29 | -20.27 | 472.2K | Off |
| 10 Apr 2026 | 9.09 AUD | 0.8% | 11.33 AUD | 13.81 AUD | -1.30 | -21.33 | 438.7K | Off |
| 3 Apr 2026 | 9.02 AUD | -8.9% | 11.38 AUD | 13.88 AUD | -1.28 | -18.91 | 594.4K | Off |
| 27 Mar 2026 | 9.90 AUD | 2.7% | 11.46 AUD | 13.94 AUD | -1.22 | -10.76 | 275.9K | Off |
| 20 Mar 2026 | 9.64 AUD | -2.9% | 11.48 AUD | 14.00 AUD | -1.12 | -12.58 | 382.5K | Off |
| 13 Mar 2026 | 9.93 AUD | -2.3% | 11.59 AUD | 14.06 AUD | -0.82 | -12.37 | 453.5K | Off |